Histamine H4 receptor as a new therapeutic target for choroidal neovascularization in age-related macular degeneration

British Journal of Pharmacology

Volumn 171, Issue 15, 2014, Pages 3754-3763

  Kaneko, Hiroki ^a   Ye, Fuxiang ^a   Ijima, Ryo ^a   Kachi, Shu ^a   Kato, Seiichi ^b   Nagaya, Masatoshi ^a   Higuchi, Akiko ^a   Terasaki, Hiroko ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

age related macular degeneration; choroidal neovascularization

Indexed keywords

1 (5 CHLORO 2 BENZIMIDAZOLYLCARBONYL) 4 METHYLPIPERAZINE; 1 (5 CHLORO 2 INDOLYLCARBONYL) 4 METHYLPIPERAZINE; HISTAMINE H4 RECEPTOR; MESSENGER RNA; 1-((5-CHLORO-1H-INDOL-2-YL)CARBONYL)-4-METHYLPIPERAZINE; ANTIBODY; ANTIHISTAMINIC AGENT; BENZIMIDAZOLE DERIVATIVE; G PROTEIN COUPLED RECEPTOR; HISTAMINE RECEPTOR; HRH4 PROTEIN, HUMAN; HRH4 PROTEIN, MOUSE; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; EXUDATIVE MACULAR DEGENERATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHOROIDAL NEOVASCULARIZATION; IMMUNOLOGY; MACULAR DEGENERATION; METABOLISM; RETINAL PIGMENT EPITHELIUM; TRANSGENIC MOUSE;

AGED; ANIMALS; ANTIBODIES; BENZIMIDAZOLES; CHOROIDAL NEOVASCULARIZATION; HISTAMINE ANTAGONISTS; HUMANS; INDOLES; MACULAR DEGENERATION; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC; PIPERAZINES; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, HISTAMINE; RETINAL PIGMENT EPITHELIUM; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84904573368     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12737     Document Type: Article

References (51)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
2. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP, (2003a). Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 48: 257-293.
3. Ambati J, Anand A, Fernandez S, Sakurai E, Lynn BC, Kuziel WA, etal. (2003b). An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat Med 9: 1390-1397.
4. Ballerini C, Aldinucci A, Luccarini I, Galante A, Manuelli C, Blandina P, etal. (2013). Antagonism of histamine H receptor exacerbates clinical and pathological signs of experimental autoimmune encephalomyelitis. Br J Pharmacol 170: 67-77.
5. Bird AC, (2010). Therapeutic targets in age-related macular disease. J Clin Invest 120: 3033-3041.
6. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, etal. (2006). Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New Engl J Med 355: 1432-1444.
7. Carmeliet P, Jain RK, (2011). Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298-307.
8. 4-Receptor Gene. Biochem Biophys Res Commun 284: 301-309.
9. Connelly W, Shenton F, Lethbridge N, Leurs R, Waldvogel H, Faull R, etal. (2009). The histamine H4 receptor is functionally expressed on neurons in the mammalian CNS. Br J Pharmacol 157: 55-63.
10. Desmadryl G, Gaboyard-Niay S, Brugeaud A, Travo C, Broussy A, Saleur A, etal. (2012). Histamine H4 receptor antagonists as potent modulators of mammalian vestibular primary neuron excitability. Br J Pharmacol 167: 905-916.
11. Dijkstra D, Leurs R, Chazot P, Shenton FC, Stark H, Werfel T, etal. (2007). Histamine downregulates monocyte CCL2 production through the histamine H4 receptor. J Allergy Clin Immunol 120: 300-307.
12. Dunford PJ, Holgate ST, (2011). The role of histamine in asthma. Adv Exp Med Biol 709: 53-66.
13. de Esch IJ, Thurmond RL, Jongejan A, Leurs R, (2005). The histamine H4 receptor as a new therapeutic target for inflammation. Trends Pharmacol Sci 26: 462-469.
14. Gantner F, Sakai K, Tusche MW, Cruikshank WW, Center DM, Bacon KB, (2002). Histamine H4 and H2 receptors control histamine-induced interleukin-16 release from human CD8+ T cells. J Pharmacol Exp Ther 303: 300-307.
15. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, (2004). Pegaptanib for neovascular age-related macular degeneration. New Engl J Med 351: 2805-2816.
16. Gutzmer R, Diestel C, Mommert S, Kother B, Stark H, Wittmann M, etal. (2005). Histamine H4 receptor stimulation suppresses IL-12p70 production and mediates chemotaxis in human monocyte-derived dendritic cells. J Immunol 174: 5224-5232.
17. Ishida S, Usui T, Yamashiro K, Kaji Y, Amano S, Ogura Y, etal. (2003). VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 198: 483-489.
18. Ito T, Komeima K, Yasuma T, Enomoto A, Asai N, Asai M, etal. (2012). Girdin and its phosphorylation dynamically regulate neonatal vascular development and pathological neovascularization in the retina. Am J Pathol 182: 586-596.
19. Jablonowski JA, Grice CA, Chai W, Dvorak CA, Venable JD, Kwok AK, etal. (2003). The first potent and selective non-imidazole human histamine H4 receptor antagonists. J Med Chem 46: 3957-3960.
20. de Jong PTVM, (2006). Mechanisms of disease: age-related macular degeneration. New Engl J Med 355: 1474-1485.
21. Kaneko H, Dridi S, Tarallo V, Gelfand BD, Fowler BJ, Cho WG, etal. (2011). DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature 471: 325-330.
22. Karlstedt K, Jin C, Panula P, (2013). Expression of histamine receptor Hrh3 and Hrh4 in rat brain endothelial cells. Br J Pharmacol 170: 58-66.
23. Kingston D, Schmid MA, Onai N, Obata-Onai A, Baumjohann D, Manz MG, (2009). The concerted action of GM-CSF and Flt3-ligand on in vivo dendritic cell homeostasis. Blood 114: 835-843.
24. Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ, etal. (2008). Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452: 591-597.
25. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
26. Kleinman ME, Kaneko H, Cho WG, Dridi S, Fowler BJ, Blandford AD, etal. (2011). Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3. Molecul Ther 20: 101-108.
27. Leurs R, Chazot PL, Shenton FC, Lim HD, de Esch IJ, (2009). Molecular and biochemical pharmacology of the histamine H4 receptor. Br J Pharmacol 157: 14-23.
28. Marneros AG, Fan J, Yokoyama Y, Gerber HP, Ferrara N, Crouch RK, etal. (2005). Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol 167: 1451-1459.
29. Martinel Lamas DJ, Croci M, Carabajal E, Crescenti EJ, Sambuco L, Massari NA, etal. (2013). Therapeutic potential of histamine H(4) receptor agonists in triple-negative human breast cancer experimental model. Br J Pharmacol 170: 188-199.
30. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
31. Miyata K, Nakamura M, Kondo M, Lin J, Ueno S, Miyake Y, etal. (2007). Reduction of oscillatory potentials and photopic negative response in patients with autosomal dominant optic atrophy with OPA1 mutations. Invest Ophthalmol Vis Sci 48: 820-824.
32. Mizutani T, Ashikari M, Tokoro M, Nozaki M, Ogura Y, (2013). Suppression of laser-induced choroidal neovascularization by a CCR3 antagonist. Invest Ophthalmol Vis Sci 54: 1564-1572.
33. Nakamura T, Itadani H, Hidaka Y, Ohta M, Tanaka K, (2000). Molecular cloning and characterization of a new human histamine receptor, HH4R. Biochem Biophys Res Commun 279: 615-620.
34. Nakayama T, Kato Y, Hieshima K, Nagakubo D, Kunori Y, Fujisawa T, etal. (2004). Liver-expressed chemokine/CC chemokine ligand 16 attracts eosinophils by interacting with histamine H4 receptor. J Immunol 173: 2078-2083.
35. Nishiguchi KM, Kataoka K, Kachi S, Komeima K, Terasaki H, (2010). Regulation of pathologic retinal angiogenesis in mice and inhibition of VEGF-VEGFR2 binding by soluble heparan sulfate. PLoS ONE 5: e13493.
36. Nishijima K, Ng Y-S, Zhong L, Bradley J, Schubert W, Jo N, etal. (2007). Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171: 53-67.
37. Oda T, Morikawa N, Saito Y, Masuho Y, Matsumoto S, (2000). Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J Biol Chem 275: 36781-36786.
38. Raffetseder U, Rauen T, Boor P, Ostendorf T, Hanssen L, Floege J, etal. (2011). Extracellular YB-1 blockade in experimental nephritis upregulates Notch-3 receptor expression and signaling. Nephron Exp Nephrol 118: e100-e108.
39. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, etal. (2006). Ranibizumab for neovascular age-related macular degeneration. New Engl J Med 355: 1419-1431.
40. Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara T, etal. (2008). Endogenous VEGF is required for visual function: evidence for a survival role on Müller cells and photoreceptors. PLoS ONE 3: e3554.
41. Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D'Amore PA, (2009). An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. PNAS 106: 18751-18756.
42. Sakurai E, Anand A, Ambati BK, van Rooijen N, Ambati J, (2003a). Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 44: 3578-3585.
43. Sakurai E, Taguchi H, Anand A, Ambati BK, Gragoudas ES, Miller JW, etal. (2003b). Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci 44: 2743-2749.
44. Takeda A, Baffi JZ, Kleinman ME, Cho WG, Nozaki M, Yamada K, etal. (2009). CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature 460: 225-230.
45. Tarallo V, Hirano Y, Gelfand BD, Dridi S, Kerur N, Kim Y, etal. (2012). DICER1 loss and alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell 149: 847-859.
46. Thurmond RL, Desai PJ, Dunford PJ, Fung-Leung WP, Hofstra CL, Jiang W, etal. (2004). A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. J Pharmacol Exp Ther 309: 404-413.
47. Tomida D, Nishiguchi KM, Kataoka K, Yasuma TR, Iwata E, Uetani R, etal. (2011). Suppression of choroidal neovascularization and quantitative and qualitative inhibition of VEGF and CCL2 by heparin. Investigat Ophthalmol Vis Sci 52: 3193-3199.
48. Yang Y, Zhang Y, Cao Z, Ji H, Yang X, Iwamoto H, etal. (2013). Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues. Proc Natl Acad Sci U S A 110: 12018-12023.
49. Zampeli E, Tiligada E, (2009). The role of histamine H4 receptor in immune and inflammatory disorders. Br J Pharmacol 157: 24-33.
50. Zhang M, Thurmond RL, Dunford PJ, (2007). The histamine H(4) receptor: a novel modulator of inflammatory and immune disorders. Pharmacol Ther 113: 594-606.
51. Zhang C, Xiong Y, Li J, Yang Y, Liu L, Wang W, etal. (2012). Deletion and down-regulation of HRH4 gene in gastric carcinomas: a potential correlation with tumor progression. PLoS ONE 7: e31207.